Investor Centre

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced it has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia for expanded reimbursement of its drug Bronchitol® for the treatment of cystic fibrosis (CF).

The PBAC, the government’s independent advisory body on medicine reimbursement, has cleared the way for Pharmaceutical Benefits Scheme (PBS) funding of Bronchitol in combination with reimbursed Pulmozyme® (another CF medication) after considering a submission from Pharmaxis at its most recent meeting.

Pharmaxis CEO Mr Gary Phillips said, “The submission for broader access to Bronchitol was strongly supported by the cystic fibrosis community with patients, families, patient organisations and CF clinic teams taking part in the feedback process. We look forward to discussing the positive PBAC recommendation with the Australian government to enable the PBS listing that will allow appropriate patients taking Pulmozyme to add reimbursed Bronchitol to their treatment regime.”

Nettie Burke, CEO of Cystic Fibrosis Australia (CFA) said, “Every individual with CF should have access to a variety of treatments which are tailored to their disease and situation. The Bronchitol delivery device is portable, and CFA strongly advocates for better, less burdensome treatments that empower people with CF to lead productive lives. We are pleased that the PBAC has made this recommendation and anticipate an early listing on the PBS.”

Pharmaxis 2017 Directors' Report and Annual Financial Statements

Updated investor presentation - 1 August 2017

Shareholder update for the quarter ending - 30 June 2017

"Insights to Fibrosis Drug Discovery & Development"

Presentation by Pharmaxis CEO Gary Phillips to 2017 Bioshares Biotech Summit, July 2017